Exelixis | EXEL - Trade Creditors


Exelixis reported $25.35M in Trade Creditors for its fiscal quarter ending in September of 2025.





Trade Creditors Change Date
Acadia Pharmaceuticals USD 21.75M 1.65M Sep/2025
Agios Pharmaceuticals USD 19.55M 2.02M Sep/2025
Amgen USD 19.64B 1.61B Sep/2025
AstraZeneca USD 25.03B 1.04B Sep/2025
Bayer EUR 6.38B 343M Sep/2025
BioMarin Pharmaceutical USD 798.44M 114.19M Sep/2025
Bristol-Myers Squibb USD 4.29B 1.14B Sep/2025
Cytokinetics USD 22.08M 46.46M Sep/2025
Eisai JPY 80.73B 2.26B Sep/2025
Eli Lilly USD 4.26B 186.5M Sep/2025
Exelixis USD 25.35M 471K Sep/2025
Genmab DKK 6M 2M Sep/2025
Glaxosmithkline GBP 21.07B 7.42B Sep/2025
Incyte USD 171.92M 1.24B Sep/2025
Ionis Pharmaceuticals USD 14.33M 8.47M Sep/2025
MacroGenics USD 5.94M 1.28M Sep/2025
Merck USD 4.15B 102M Sep/2025
Moderna USD 267M 92M Sep/2025
Neurocrine Biosciences USD 119.9M 15.3M Sep/2025
Novartis USD 4.56B 49M Sep/2025
Pfizer USD 5.02B 142M Sep/2025
Sanofi EUR 22.93B 2.89B Dec/2025
Takeda JPY 467.59B 28.61B Dec/2025
Ultragenyx Pharmaceutical USD 40.57M 6.33M Sep/2025
Xencor USD 9.08M 9.45M Sep/2025